# NF2

## Overview
The NF2 gene, located on chromosome 22, encodes the protein merlin, also known as moesin-ezrin-radixin like (MERLIN) tumor suppressor. Merlin is a member of the protein 4.1 superfamily and shares structural similarities with the ERM (ezrin, radixin, moesin) proteins, functioning primarily as a tumor suppressor. It plays a critical role in linking the actin cytoskeleton to the plasma membrane, thereby regulating cell proliferation, motility, and survival. The protein is involved in several key signaling pathways, including the PI3-kinase/Akt, wnt, and Hippo pathways, where it acts to inhibit cell growth and promote apoptosis. Mutations in the NF2 gene are associated with neurofibromatosis type 2, a disorder characterized by the development of benign tumors in the nervous system, particularly affecting the auditory nerves (PećinaŠlaus2013Merlin; Asthagiri2009Neurofibromatosis).

## Structure
The NF2 gene encodes the protein merlin, which is a member of the protein 4.1 family and shares structural similarities with the ERM (ezrin, radixin, moesin) family. Merlin features an N-terminal FERM domain, an α-helical domain, and a C-terminal domain. These domains are crucial for its function in linking actin to plasma membrane proteins and acting as a tumor suppressor (Kim2020Characterization; Pradilla2003Gene).

Merlin undergoes post-translational modifications, such as phosphorylation, which influence its activity and interactions. These modifications are important for regulating its role in cell signaling and cytoskeletal organization (Pradilla2003Gene).

The NF2 gene also has multiple splice variants, which affect the functional properties of merlin. These variants can lead to differences in the protein's ability to interact with other cellular components and perform its tumor suppressor functions (Pradilla2003Gene).

While specific details on the primary, secondary, tertiary, and quaternary structures of merlin are not provided in the context, the presence of distinct domains and post-translational modifications highlights its complex structural and functional nature.

## Function
The NF2 gene encodes the protein merlin, which functions as a tumor suppressor involved in regulating cell proliferation, motility, survival, and signaling pathways. In healthy human cells, merlin plays a crucial role in maintaining normal cell growth by interacting with the actin cytoskeleton and other cellular components (PećinaŠlaus2013Merlin; Gutmann2001Functional). Merlin is structurally related to the Protein 4.1 family, which includes ERM proteins (ezrin, radixin, and moesin), and it acts as a linker between the plasma membrane and the cytoskeleton (PećinaŠlaus2013Merlin; Gutmann2001Functional).

Merlin is involved in several signaling pathways, including the PI3-kinase/Akt and wnt pathways, where it suppresses cell growth by inhibiting specific signaling components (PećinaŠlaus2013Merlin). It also regulates the Hippo pathway, which is important for tumor suppression by restricting proliferation and promoting apoptosis (PećinaŠlaus2013Merlin). Merlin's activity is modulated by its conformation, which is influenced by phosphorylation; the closed conformation is active and functions as a tumor suppressor (PećinaŠlaus2013Merlin). In its active form, merlin helps maintain contact inhibition of proliferation and regulates adhesion to the extracellular matrix, preventing uncontrolled cell growth (PećinaŠlaus2013Merlin).

## Clinical Significance
Mutations in the NF2 gene, which encodes the tumor suppressor protein merlin, are primarily associated with neurofibromatosis type 2 (NF2), an autosomal dominant disorder. This condition is characterized by the development of multiple benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas (Ghalavand2023The; Asthagiri2009Neurofibromatosis). NF2 mutations can be inherited or occur de novo, with more than 50% of cases resulting from new mutations (Evans2009Neurofibromatosis). The hallmark of NF2 is the presence of bilateral vestibular schwannomas, which can lead to hearing loss, tinnitus, and balance dysfunction (Evans2009Neurofibromatosis; Ahronowitz2007Mutational).

The NF2 gene is also implicated in other conditions. Somatic mutations in NF2 are found in sporadic meningiomas and schwannomas, and the gene is occasionally inactivated in sporadic mesotheliomas and perineuriomas (Ahronowitz2007Mutational; Evans2005Multiple). The severity of NF2 can vary depending on the type of mutation, with truncating mutations often leading to a more severe phenotype (Evans1998Genotypephenotype). Mosaicism, where only a proportion of cells carry the mutation, can result in milder disease presentations (Evans2009Neurofibromatosis).

## Interactions
The NF2 gene encodes the protein merlin, which is involved in various protein interactions crucial for its tumor suppressor function. Merlin interacts with the actin-based cytoskeleton, and its localization at the plasma membrane is essential for its role in tumor suppression. This interaction is mediated by the N-terminal domain, which is crucial for membrane localization, while the C-terminal domain enhances interaction with actin (Deguen1998Impaired). 

Merlin also interacts with proteins in the ERM family, such as ezrin, in a head-to-tail orientation. This interaction is isoform-specific, with isoform I binding only to ezrin with an exposed carboxy-terminus, while isoform II can bind regardless of conformation (Meng2000Interaction). Additionally, merlin interacts with the protein SCHIP-1, a novel partner that binds specifically to certain spliced isoforms and mutant forms of merlin, suggesting that conformational changes regulate this interaction (Goutebroze2000Cloning).

The FERM domain of merlin is critical for its interactions, including with erythrocyte p55, a scaffolding protein involved in cell shape and neural patterning. This interaction may play a role in regulating apicobasal polarity and tumor suppression pathways (Seo2009Identification).


## References


[1. (PećinaŠlaus2013Merlin) Nives Pećina-Šlaus. Merlin, the nf2 gene product. Pathology &amp; Oncology Research, 19(3):365–373, May 2013. URL: http://dx.doi.org/10.1007/s12253-013-9644-y, doi:10.1007/s12253-013-9644-y. This article has 37 citations.](https://doi.org/10.1007/s12253-013-9644-y)

[2. (Meng2000Interaction) Jin-Jun Meng, D.J. Lowrie, Hao Sun, Emily Dorsey, Patricia D. Pelton, Anne-Marie Bashour, Joanna Groden, Nancy Ratner, and Wallace Ip. Interaction between two isoforms of the nf2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of erm proteins by merlin. Journal of Neuroscience Research, 62(4):491–502, 2000. URL: http://dx.doi.org/10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D, doi:10.1002/1097-4547(20001115)62:4<491::aid-jnr3>3.0.co;2-d. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/1097-4547(20001115)62:4)

[3. (Evans2009Neurofibromatosis) DGareth R Evans. Neurofibromatosis type 2 (nf2): a clinical and molecular review. Orphanet Journal of Rare Diseases, June 2009. URL: http://dx.doi.org/10.1186/1750-1172-4-16, doi:10.1186/1750-1172-4-16. This article has 391 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1750-1172-4-16)

[4. (Kim2020Characterization) Eunhye Kim, Mirae Kim, Kyungha So, Young Seok Park, Chang Gok Woo, and Sang-Hwan Hyun. Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors. Cancer Cell International, July 2020. URL: http://dx.doi.org/10.1186/s12935-020-01438-x, doi:10.1186/s12935-020-01438-x. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-020-01438-x)

[5. (Seo2009Identification) Pil-Soo Seo, Brendan J. Quinn, Anwar A. Khan, Lixiao Zeng, Christos G. Takoudis, Toshihiko Hanada, Annalisa Bolis, Alessandra Bolino, and Athar H. Chishti. Identification of erythrocyte p55/mpp1 as a binding partner of nf2 tumor suppressor protein/merlin. Experimental Biology and Medicine, 234(3):255–262, March 2009. URL: http://dx.doi.org/10.3181/0809-rm-275, doi:10.3181/0809-rm-275. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3181/0809-rm-275)

[6. (Evans2005Multiple) D G R Evans. Multiple meningiomas: differential involvement of the nf2 gene in children and adults. Journal of Medical Genetics, 42(1):45–48, January 2005. URL: http://dx.doi.org/10.1136/jmg.2004.023705, doi:10.1136/jmg.2004.023705. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2004.023705)

[7. (Pradilla2003Gene) Gustavo Pradilla, Tony Azzam, Paul P Wang, Abraham J Domb, and Henry Brem. Gene therapy for malignant brain tumors. Expert Review of Neurotherapeutics, 3(5):685–701, September 2003. URL: http://dx.doi.org/10.1586/14737175.3.5.685, doi:10.1586/14737175.3.5.685. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1586/14737175.3.5.685)

[8. (Asthagiri2009Neurofibromatosis) Ashok R Asthagiri, Dilys M Parry, John A Butman, H Jeffrey Kim, Ekaterini T Tsilou, Zhengping Zhuang, and Russell R Lonser. Neurofibromatosis type 2. The Lancet, 373(9679):1974–1986, June 2009. URL: http://dx.doi.org/10.1016/s0140-6736(09)60259-2, doi:10.1016/s0140-6736(09)60259-2. This article has 471 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0140-6736(09)60259-2)

[9. (Deguen1998Impaired) B Deguen. Impaired interaction of naturally occurring mutant nf2 protein with actin-based cytoskeleton and membrane. Human Molecular Genetics, 7(2):217–226, February 1998. URL: http://dx.doi.org/10.1093/hmg/7.2.217, doi:10.1093/hmg/7.2.217. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/7.2.217)

[10. (Gutmann2001Functional) D. H. Gutmann. Functional analysis of neurofibromatosis 2 (nf2) missense mutations. Human Molecular Genetics, 10(14):1519–1529, July 2001. URL: http://dx.doi.org/10.1093/hmg/10.14.1519, doi:10.1093/hmg/10.14.1519. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/10.14.1519)

[11. (Evans1998Genotypephenotype) D G Evans, L Trueman, A Wallace, S Collins, and T Strachan. Genotype/phenotype correlations in type 2 neurofibromatosis (nf2): evidence for more severe disease associated with truncating mutations. Journal of Medical Genetics, 35(6):450–455, June 1998. URL: http://dx.doi.org/10.1136/jmg.35.6.450, doi:10.1136/jmg.35.6.450. This article has 156 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.35.6.450)

[12. (Goutebroze2000Cloning) Laurence Goutebroze, Estelle Brault, Christian Muchardt, Jacques Camonis, and Gilles Thomas. Cloning and characterization of schip-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant nf2 proteins. Molecular and Cellular Biology, 20(5):1699–1712, March 2000. URL: http://dx.doi.org/10.1128/mcb.20.5.1699-1712.2000, doi:10.1128/mcb.20.5.1699-1712.2000. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.5.1699-1712.2000)

[13. (Ghalavand2023The) Mohammad Amin Ghalavand, Alimohamad Asghari, Mohammad Farhadi, Farzad Taghizadeh-Hesary, Masoud Garshasbi, and Masoumeh Falah. The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell International, May 2023. URL: http://dx.doi.org/10.1186/s12935-023-02940-8, doi:10.1186/s12935-023-02940-8. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-023-02940-8)

[14. (Ahronowitz2007Mutational) Iris Ahronowitz, Winnie Xin, Rosemary Kiely, Katherine Sims, Mia MacCollin, and Fabio P. Nunes. Mutational spectrum of thenf2gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Human Mutation, 28(1):1–12, January 2007. URL: http://dx.doi.org/10.1002/humu.20393, doi:10.1002/humu.20393. This article has 78 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20393)